Parkinson Disease
Conditions
Brief summary
This study will investigate disparities in neurocognitive impairment (NCI) among Hispanics/Latinos/as/x (henceforth Hispanics) living in the US-Mexico borderland of California or in North Carolina with Parkinson's Disease (PD) and determine mechanisms underlying these disparities. NCI is an important aspect of the clinical course of PD, particularly among Hispanics, who have increased prevalence of dementia. Among the many potential factors driving this disparity, the investigators chose to focus on a modifiable risk factor to which Hispanics are particularly vulnerable, and that has been linked to increased NCI, namely cardiovascular (CVD) risk (e.g., diabetes, hypertension, obesity).
Detailed description
The proposed study will use a cross-sectional design to determine the presence of NCI in 120 persons with PD (age 40+), living in the US-Mexico borderland of California or in North Carolina, including 60 Hispanics and 60 non-Hispanic Whites. All participants will complete comprehensive neuromedical and neuropsychological evaluations, a blood draw and assessments of socio-cultural factors (e.g., health literacy, access to care, acculturation, bilingualism, discrimination, socioeconomic status). Using these data we will examine the extent to which CVD risk (e.g., diabetes, hypertension, obesity), PD severity and social determinants of health drive NCI among Hispanics with PD. The present proposal will capitalize on the infrastructure and expertise available at Duke University and will follow a community-based participatory research approach to complete the proposed study aims.
Interventions
OTHERWill examine how Cardiovascular Disease risk, PD severity and social determinants impact neurocognitive impairment in Hispanics vs non-Hispanics Whites
All participants will complete comprehensive neuromedical and neuropsychological evaluations, a blood draw and assessments of socio-cultural factors (e.g., health literacy, access to care, acculturation, bilingualism, discrimination, socioeconomic status).
Sponsors
Duke University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 40 years old and older * non-Hispanic Whites * Hispanics * All genders * Ability to provide consent * Diagnosed with Parkinson's Disease
Exclusion criteria
* Other neurological illness/diagnosis * Injury that would affect cognition (i.e. stroke, closed head injury with loss of consciousness for longer than 30 minutes)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Language (Letter Fluency) | Day 1 (day of enrollment) | — |
| Language (Animal Fluency) | Day 1 (day of enrollment) | — |
| Language (Vegetable Fluency) | Day 1 (day of enrollment) | — |
| Language (Multilingual Naming Test) | Day 1 (day of enrollment) | — |
| Speed of Information Processing | Day 1 (day of enrollment) | Trail Making Test A |
| Attention/Working Memory | Day 1 (day of enrollment) | PASAT-50 (Paced Auditory Serial Addition Test) |
| Executive Function | Day 1 (day of enrollment) | Trail Making Test B |
| Verbal Learning and Memory | Day 1 (day of enrollment) | Hopkins Verbal Learning Test-Revised |
| Visual Learning and Memory | Day 1 (day of enrollment) | Brief Visuospatial Memory Test - Revised, Benson Figure Delay |
| Visual-Spatial skills | Day 1 (day of enrollment) | Benson Figure Copy |
| Everyday Functioning | Day 1 (day of enrollment) | Modified Lawton-Brody Instrumental Activities of Daily Living questionnaire |
| Diagnosis of MCI/dementia in PD | Day 1 (day of enrollment) | Objective presence of MCI and dementia in PD will be determined via comprehensive diagnostic criteria |
| diabetes mellitus | Day 1 (day of enrollment) | fasting plasma glucose \>126 mg/dL, an HbA1c \>6.5%, or use of antihyperglycemic medications |
| hypercholesterolemia and dyslipidemia | Day 1 (day of enrollment) | total cholesterol \>240 mg/dL, LDL cholesterol \>160 mg/dL, or HDL cholesterol \<40 mg/dL or on cholesterol-lowering medication |
| hypertension | Day 1 (day of enrollment) | systolic blood pressure \>140 mm Hg, diastolic blood pressure \>90 mm Hg, or on antihypertensive medication |
| current cigarette smoking | Day 1 (day of enrollment) | Self-report |
| obesity | Day 1 (day of enrollment) | BMI of \>30.0 |
| Parkinson's disease severity | Day 1 (day of enrollment) | Movement Disorders Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) |
Countries
United States
Outcome results
None listed